Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $30.00 at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target hoisted by stock analysts at UBS Group from $28.00 to $30.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price objective indicates a potential upside of 38.03% from the company’s previous close.

Several other equities analysts also recently commented on the company. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Barclays boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.63.

Teva Pharmaceutical Industries Stock Down 0.3 %

TEVA opened at $21.74 on Thursday. The stock has a market cap of $24.62 billion, a price-to-earnings ratio of -25.57, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm’s fifty day moving average is $19.74 and its 200 day moving average is $18.38. Teva Pharmaceutical Industries has a fifty-two week low of $11.48 and a fifty-two week high of $22.80.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Claro Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter worth about $52,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.